Key result
LMWH improves pregnancy outcomes compared with previous untreated pregnancies in high-risk women.
Why the study?
Pregnant women at risk of venous thromboembolism or adverse pregnancy outcomes have been treated with oral anticoagulants or unfractionated heparin, which have fetal or maternal side effects, while the safety and efficacy of long-term LMWH use in pregnancy remain to be established.
Does prophylactic or therapeutic low-molecular-weight heparin improve pregnancy outcomes and prevent venous thromboembolism in pregnant women at risk?
Population
114 pregnant women with 130 pregnancies at risk of venous thromboembolism or adverse outcomes
Comparison
Prophylactic or therapeutic LMWH treatment vs previous untreated pregnancies
Design
Prospective cohort study
Follow-up
January 2004 to February 2007
Authors
Loading...
LMWH prophylaxis was associated with no recurrent VTE and fewer miscarriages; leaves open whether randomized trials will confirm benefit.
Cohort (n=114)
Does prophylactic or therapeutic low-molecular-weight heparin improve pregnancy outcomes and prevent venous thromboembolism in pregnant women at risk?
p-value: p=< 0.0001
Long-term administration of low-molecular-weight heparins in high-risk pregnancies appears safe and significantly improves pregnancy outcomes compared to prior untreated pregnancies.
Santoro et al. (2009) conducted a cohort in Pregnancy at risk of venous thromboembolism or adverse outcomes (n=114). Low-molecular-weight heparins (LMWHs) vs. Previous untreated pregnancies was evaluated on Pregnancy outcome (p=< 0.0001). Low-molecular-weight heparins significantly improved pregnancy outcomes and decreased absolute and relative risks compared with previous untreated pregnancies (P < 0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: